Indaptus Free Cash Flow Operating Cash Flow Ratio from 2010 to 2025

INDP Stock  USD 11.60  0.29  2.56%   
Indaptus Therapeutics Free Cash Flow Operating Cash Flow Ratio yearly trend continues to be relatively stable with very little volatility. Free Cash Flow Operating Cash Flow Ratio is likely to grow to 1.25 this year. During the period from 2010 to 2025, Indaptus Therapeutics Free Cash Flow Operating Cash Flow Ratio destribution of quarterly values had range of 0.4397 from its regression line and mean deviation of  0.12. View All Fundamentals
 
Free Cash Flow Operating Cash Flow Ratio  
First Reported
2010-12-31
Previous Quarter
1.17
Current Value
1.25
Quarterly Volatility
0.14842741
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Indaptus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Indaptus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 698, Other Operating Expenses of 14.7 M or Research Development of 9.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.9. Indaptus financial statements analysis is a perfect complement when working with Indaptus Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Indaptus Stock
Check out the analysis of Indaptus Therapeutics Correlation against competitors.
To learn how to invest in Indaptus Stock, please use our How to Invest in Indaptus Therapeutics guide.

Latest Indaptus Therapeutics' Free Cash Flow Operating Cash Flow Ratio Growth Pattern

Below is the plot of the Free Cash Flow Operating Cash Flow Ratio of Indaptus Therapeutics over the last few years. It is Indaptus Therapeutics' Free Cash Flow Operating Cash Flow Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Indaptus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Free Cash Flow Operating Cash Flow Ratio10 Years Trend
Pretty Stable
   Free Cash Flow Operating Cash Flow Ratio   
       Timeline  

Indaptus Free Cash Flow Operating Cash Flow Ratio Regression Statistics

Arithmetic Mean1.13
Geometric Mean1.13
Coefficient Of Variation13.08
Mean Deviation0.12
Median1.05
Standard Deviation0.15
Sample Variance0.02
Range0.4397
R-Value(0.26)
Mean Square Error0.02
R-Squared0.07
Significance0.32
Slope(0.01)
Total Sum of Squares0.33

Indaptus Free Cash Flow Operating Cash Flow Ratio History

2024 1.17
2022 1.01
2020 1.0
2019 1.03
2018 1.25
2017 1.23
2016 1.04

About Indaptus Therapeutics Financial Statements

Indaptus Therapeutics shareholders use historical fundamental indicators, such as Free Cash Flow Operating Cash Flow Ratio, to determine how well the company is positioned to perform in the future. Although Indaptus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Indaptus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Indaptus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Free Cash Flow Operating Cash Flow Ratio 1.17  1.25 

Additional Tools for Indaptus Stock Analysis

When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.